SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration

Katja Eloranta
Marjut Pihlajoki
Emmi Liljestrom
Ruth Nousiainen
Tea Soini

See next page for additional authors
Authors
Katja Eloranta, Marjut Pihlajoki, Emmi Liljeström, Ruth Nousiainen, Tea Soini, Jouko Lohi, Stefano Cairo, David B Wilson, Seppo Parkkila, and Markku Heikinheimo
SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration

Katja Eloranta1, Marjut Pihlajoki1, Emmi Liljeström1, Ruth Nousiainen1, Tea Soini1, Jouko Lohi2, Stefano Cairo3,4,5, David B. Wilson6,7, Seppo Parkkila8,9,10 and Markku Heikinheimo1,6,11

1Pediatric Research Center, Children’s Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 2Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Xentech, Evry, Evry, France, 4Istituto di Ricerca Pediatrica, Padova, Italy, 5Champions Oncology, Hackensack, NJ, United States, 6Department of Pediatrics, Washington University School of Medicine, St. Louis Children’s Hospital, St. Louis, MO, United States, 7Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, United States, 8Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, 9FICAN Mid, Tampere University, Tampere, Finland, 10Fimlab Ltd, Tampere University Hospital, Tampere, Finland, 11Faculty of Medicine and Health Technology, Center for Child, Adolescent, and Maternal Health Research, Tampere University, Tampere, Finland

Background: In response to hypoxia, tumor cells undergo transcriptional reprogramming including upregulation of carbonic anhydrase (CA) IX, a metalloenzyme that maintains acid-base balance. CAIX overexpression has been shown to correlate with poor prognosis in various cancers, but the role of this CA isoform in hepatoblastoma (HB) has not been examined.

Methods: We surveyed the expression of CAIX in HB specimens and assessed the impact of SLC-0111, a CAIX inhibitor, on cultured HB cells in normoxic and hypoxic conditions.

Results: CAIX immunoreactivity was detected in 15 out of 21 archival pathology HB specimens. The CAIX-positive cells clustered in the middle of viable tumor tissue or next to necrotic areas. Tissue expression of CAIX mRNA was associated with metastasis and poor clinical outcome of HB. Hypoxia induced a striking upregulation of CAIX mRNA and protein in three HB cell models: the immortalized human HB cell line HUH6 and patient xenograft-derived lines HB-295 and HB-303. Administration of SLC-0111 abrogated the hypoxia-induced upregulation of CAIX and decreased HB cell viability, both in monolayer and spheroid cultures. In addition, SLC-0111 reduced HB cell motility in a wound healing assay. Transcriptomic changes triggered by SLC-0111 administration differed under normoxic vs. hypoxic conditions, although SLC-0111 elicited upregulation of several tumor suppressor genes under both conditions.
1 Introduction

Hepatoblastoma (HB) is a rare pediatric liver malignancy with an incidence of 2.16 per million person-years (1). Approximately 80% of cases are diagnosed before the age of three years (2). Although the etiology of HB is not well understood, its morphology and molecular landscape suggest an embryonal origin (3–5). Most HB cases are sporadic, but certain congenital disorders such as Beckwith-Wiedemann syndrome and familial adenomatous polyposis are risk factors for HB development (3). HB treatment entails surgical resection or liver transplantation combined with pre- and post-operative administration of cisplatin, carboplatin, and doxorubicin (6). This approach has improved the 5-year overall survival (OS) rate to greater than 80% (7), though patients with metastases or relapsed/refractory disease have significantly lower survival rates, emphasizing the need for novel treatment strategies (8).

Solid tumors often contain hypoxic regions due to an imbalance between microvascularization and rapid growth (9). The hypoxic microenvironment is associated with cancer progression and treatment failure (10). Cancer cells adapt to low oxygen tension via hypoxia inducible factor 1α (HIF1α) mediated responses including upregulation of carbonic anhydrase (CA) IX (11). CAs are evolutionary conserved metalloenzymes catalyzing reversible hydration of CO2 to HCO3− and H+ (12). In humans, fifteen CA isoforms have been identified, three of which lack catalytic activity (13). Transmembrane CAIX is a tumor associated CA isoform with restricted expression in healthy tissue (14). In fetal liver, scattered CAIX-positive hepatocytes have been reported, but postnatal CAIX immunoreactivity in liver is limited to bile duct cells (15–17).

High CAIX expression has been linked to enhanced cell survival, high proliferation rate, increased motility/invasion, and chemoresistance in a wide range of tumors including breast, lung, and oral cancers (18–20). CAIX plays a pivotal role in maintaining acid-base balance in tumors (21). While intracellular acidification reduces tumor cell survival and can be utilized to kill cancer cells, an acidic extracellular milieu supports tumor progression (22). CAIX drives both neutralization of the intracellular compartment and acidification of the tumor microenvironment, promoting an aggressive cancer phenotype (23). Consequently, CAIX is an attractive therapeutic target. A small molecule inhibitor of CAIX, SLC-0111, has completed a phase 1 clinical trial for treatment of advanced solid tumors; no significant dose-limiting toxicities were encountered (24).

Herein, we characterize CAIX expression in archival HB specimens and use cell culture models to study the impact of SLC-0111 on this malignancy. We show that hypoxia induces CAIX expression in HB cells and that SLC-0111 has considerable in vitro activity against this cancer.

2 Materials and methods

2.1 Patient samples

Samples were acquired from the Helsinki Biobank at Helsinki University Hospital. Informed written consent was collected at the time of sample deposit. The study was approved by an ethics committee at Helsinki University Hospital (HUS/3319/2018) and was performed in accordance with Finnish bylaws. Tumor samples (n=21) were obtained from HB patients treated at Children’s Hospital, Helsinki University Hospital between January 1, 1990 and December 31, 2017. Sampling was performed during surgical resection or liver transplantation (after pre-operative chemotherapy). Normal liver (NL) control samples were collected from organ donors (n=3).

2.2 Immunohistochemistry

Five µm sections of formalin-fixed paraffin embedded tumor specimens were deparaffinized and immunostained with a monoclonal anti-human CAIX antibody (M75) (25). Immunoperoxidase staining was performed using an automated Lab Vision Autostainer 480 (LabVision Corporation, Fremont, CA, USA) and Power Vision+ Poly-HRP Immunohistochemistry kit reagents (ImmunoVision Technologies Co). The staining protocol included the following steps: (a) rinsing in wash buffer; (b) treatment in 3% H2O2 in ddH2O for five minutes and rinsing with wash buffer; (c) blocking with cow colostrum diluted 1:2 in Tris-buffered saline (TBS) containing 0.05% Tween-20 for 30 minutes and rinsing in wash buffer; (d) incubation with 1:100 diluted M75 for 30 minutes; (e) rinsing in wash buffer three times for five minutes each; (f) incubation with poly-HRP-conjugated anti-mouse IgG for 30 minutes and rinsing in wash buffer three times for five minutes each; (g)

Abbreviations: ACOT12, acyl-CoA thioesterase 12; ACTB, actin beta; ADRA2A, adrenoceptor alpha 2A; AQP10, aquaporin 10; CA, carbonic anhydrase; CAIX, carbonic anhydrase IX; CDK, cyclin dependent kinase; CHUK, nuclear factor NF-kappa-B inhibitor kinase alpha; CSC, cancer stem cell; DMSO, dimethyl sulfoxide; DEG, differential gene expression; GABRA2, gamma-aminobutyric acid receptor subunit alpha-2; HB, hepatoblastoma; HDAC, histone deacetylase; IKBKB, nuclear factor NF-kappa-B inhibitor kinase beta; MT, metallocothionein PDX, patient-derived xenografts; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinases; PPIG, peptidyl-prolyl cis-trans isomerase G; RFX6, regulatory factor X6; TSYT, thymylidate synthase; tumor progression (22). CAIX drives both neutralization of the intracellular compartment and acidification of the tumor microenvironment, promoting an aggressive cancer phenotype (23). Consequently, CAIX is an attractive therapeutic target. A small molecule inhibitor of CAIX, SLC-0111, has completed a phase 1
incubation in DAB (3,3’-diaminobenzidine tetrahydrochloride) solution (one drop of DAB solution A and one drop of DAB solution B in 1 ml of ddH2O) for six minutes and rinsing in ddH2O; (h) CuSO4 treatment for five minutes to enhance the signal and rinsing in ddH2O; (i) treatment with hematoxylin for one minute; (j) rinsing with ddH2O. All steps were performed at room temperature (RT). Imaging was performed using 3DHISTECH Panoramic 250 FLASH II digital slide scanner at Genome

2.6 RNA and protein extraction

RNA and protein extraction was performed with Nucleospin RNA/Protein Mini extraction kit (Macherey-Nagel, Düren, Germany) following the manufacturer’s instructions.

2.7 RNA sequencing and data processing

HUH6 cells were cultured under normoxic or hypoxic conditions and treated with 100 µM of SLC-0111 or vehicle. RNA was extracted after 48 h incubation. Prior to sequencing, RNA concentration, quality, and integrity were assessed by the Biomedicum Functional Genomics Unit (Helsinki Institute of Life Science and Biocenter Finland, University of Helsinki, Finland) using the TapeStation system (Agilent, Glostrup, Denmark). RNA libraries were prepared applying polyA selection, and Illumina compatible cDNA libraries were constructed by GENEWIZ (Leipzig, Germany). Subsequently, samples were sequenced on Illumina NovaSeq 6000 yielding 2x150bp paired end reads (GENEWIZ). An RNA sequencing dataset containing 11 HB patient samples and 11 NL samples was obtained from the GEO database of NCBI (accession number: GSE151347) (31, 32). FastQC tool was utilized to control quality of the reads (33). Sequenced reads were mapped to human reference genome hg38 using HISAT2 aligner (34). Reads per gene were counted with HTSeq (35). To analyze differentially expressed genes (DEGs), edgeR2 tool was employed (36). Cut-off values were set to fold change lg2 +/−0.8 and Benjamini-Hochberg adjusted p-value <0.05. Preprocessing of data and DEG analysis was carried out with Chipster (26). Gene Ontology (GO) analysis was performed with Enrichr (37, 38). R packages tidyverse and ggplot2 were used for data visualization in R (v. 4.0.3).

2.8 Real-time quantitative PCR (RT-qPCR)

RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) following the manufacturer’s instructions. RT-qPCR was carried out with a CFX384 thermocycler instrument (Bio-Rad), and PowerUP SYBR Green Master Mix (Thermo Fisher Scientific) was used for gene amplification. Relative gene expression was assessed using the 2−ΔΔCt method (39). Geometric mean of ACTB and PPIG expression served as a reference. Primer sequences were: ACTB; TCAGCGAT (reverse); CAIX; TTCCATACCCAAGAAGG (forward), TCTGAGCCTTCCCAATGGCCAACAGAGGGAAG (reverse). Each cell line was authenticated through short tandem repeat profiling.

2.9 Western blotting

Proteins (10 µg) were separated by electrophoresis using Mini-Protein TGX Stain-Free Gels (Bio-Rad, Hercules, CA, USA). Next, proteins were transferred onto polyvinyl fluoride membrane. Blocking was performed with 5% non-fat milk in TBS. Primary antibody incubations were performed at +4°C for overnight (anti-
human CAIX rabbit IgG at a of dilution 1:1500; NB100-417, Novus Biologicals, Littleton, CO, USA). Secondary antibody incubation was carried out at RT for 1 h (1:10,000; #111-035-144, Jackson ImmunoResearch, West Grove, PA, USA). Protein bands were illuminated using the Enhanced Chemiluminescence detection kit (Amersham ECL reagent; GE Healthcare, Barrington, IL, USA). Quantification was performed with Image Lab Software 6.0 (Bio-Rad). CAIX band intensities were normalized to the amount of total protein in the corresponding lane using stain-free technology (37).

2.10 Wound healing assay

Ibidi-treated cell culture inserts (3-well in μ-dish; Ibidi, Munich, Germany) were used to generate wounds. Cells were seeded into inserts in high density 24 h prior to the experiment. Before treatment initiation with vehicle or 100 μM of SLC-0111, inserts were removed, and cells were washed with phosphate buffered saline (PBS) to eliminate debris. Wounds were imaged at treatment outset (0 h) and after 20 h with an Eclipse TS100 microscope supplemented with the DS-Fi1 digital imaging system (Nikon, Tokyo, Japan). Wounds (16 images/insert) were analyzed with ImageJ software to calculate the percentage of wound closure. The following formula was used: Wound closure (%) = ((W₀ − Wᵣ)/W₀) x 100 (W₀ = Wound area at 0 h and Wᵣ = Wound area at 20 h).

2.11 Spheroid cultures

Cells were seeded at a density of 2000 cells/well into 96-well ultra-low attachment plates (PerkinElmer, Waltham, MA, USA) and cultured without disturbance for 48 h at +37°C in a humidified incubator with 5% CO₂. After the establishment period, cells were incubated with vehicle or increasing concentrations of SLC-0111 for 48 h.

2.12 Viability measurements

Cell viability (ATP concentration) was assessed with the ATPLite™ 2D or 3D monitoring system (PerkinElmer) following manufacturer’s instructions. Luminescence was measured with a GloMax microplate reader (Promega, Madison, WI, USA).

2.13 Immunofluorescence

HUH6 and HB-303 cells (100,000 cells/well) were grown in 4-well chamber slides coated with collagen I for 24 h. Cells were fixed with 4% paraformaldehyde. Non-specific binding was blocked with UltraVision Protein Block solution (Thermo Scientific, Fremont, CA, USA). Next, cells were incubated with primary antibody at room temperature for 1 h (NB100-417 human anti-rabbit CAIX at 1:1000 dilution, Novus Biologicals, Littleton, CO, USA). Secondary antibody incubation was performed with goat anti-rabbit IgG (H+L) AlexaFluor 647 (1 h, room temperature) at 1:800 dilution (A32733, Invitrogen, Carlsbad, CA, USA). Images were captured with a Zeiss Axio Imager M2 (objective: EC Plan Neofluor 40 X/0.75 Ph2 M27) (Carl-Zeiss, Oberkochen, Germany).

Spheroids were fixed with chilled 100% methanol for 20 minutes at RT. Following washes with PBS, 0.1% Triton-X was utilized to permeabilize the cells. Nonspecific binding was blocked with UltraVision Protein Block Solution (Thermo Fisher). Primary antibody incubation (anti-human CAIX rabbit IgG, at a dilution of 1:100; NB100-417, Novus Biologicals) was performed at RT for 1.5 h. Subsequently, spheroids were incubated with secondary antibody (anti-rabbit IgG (H+L) AlexaFluor 647, at dilution 1:200; A32733, Thermo Fisher) at RT for 1 h. Hoechst (at dilution 1:2000; #62249, Thermo Fisher) was used for nuclear staining. Opera Phenix High Content Screening System was employed to capture images (Perkin Elmer). Imaging was performed in the High Content Imaging and Analysis unit (FIMM, University of Helsinki).

2.14 Target prediction analyses

Potential bioactive targets of SLC-0111 were assessed with SwissTargetPrediction (http://www.swisstargetprediction.ch/) (40) and SUPERpred (https://prediction.charite.de) (41) online tools.

2.15 Statistical analysis

Cell experiments were conducted in triplicate. Statistical analyses were carried out with GraphPad Prism (v. 8.4.2; San Diego, CA, USA). Student’s t-test or one-way ANOVA followed with Tukey’s test were utilized to assess statistical significance depending on the experimental setting. p-value < 0.05 was considered significant.

3 Results

3.1 CAIX protein expression in clinical HB samples

We analyzed 21 specimens of HB (11 male, 10 female) in the Helsinki Biobank. The median patient age at surgery was 3.18 years (0.23-10.83 years). Patient characteristics, treatments, and CAIX expression status are summarized in Table 1. Three pediatric donor liver samples (age 2.0-8.2 years) were used as normal controls. Consistent with previous studies, in healthy liver CAIX immunostaining was restricted to bile duct cells (Figures 1A, B) (16, 17). Over 70% of the HB specimens demonstrated CAIX immunoreactivity; 9/21 had intermediate (Figures 1C, D) expression, and 6/21 had high CAIX expression (Figures 1E, F). CAIX staining was predominantly membranous in both the HB and healthy liver samples (Figures 1A–F). Within HB specimens, CAIX-positive cells were grouped in small clusters in the middle of viable tissue (Figures 1C, D) or adjacent to necrotic areas (Figures 1E, F), regions presumed to be hypoxic due to limited blood supply.
3.2 CAIX mRNA expression in HB correlates with poor clinical outcome

In the Helsinki cohort, all 5 cases of metastatic HB demonstrated CAIX immunoreactivity (Table 1), suggesting that CAIX expression correlates with advanced disease. We used a larger patient cohort [GSE131329, a dataset containing 53 HB and 14 normal liver samples] to compare CAIX mRNA expression with three clinical variables – occurrence of an unfavorable event, metastasis, and overall survival. Total CAIX expression was higher in normal liver (median 7.485, [IQR 7.308–7.613]) than in HB samples (median 7.260, [IQR 7.115–7.470]) (Figure 2A), likely a reflection of CAIX expression in the biliary epithelium of normal tissue. The occurrence of any event was associated with higher CAIX expression (median 7.360 [IQR 7.245–7.640]) than an event-free disease course (median 7.145 [IQR 7.075–7.376]) (Figure 2B). Patients with distant metastases had higher CAIX expression (median 7.470 [IQR 7.223–7.638]) than those without metastases (median 7.170 [IQR 7.110–7.380]) (Figure 2C). Poor overall survival was associated with elevated CAIX expression (HB median 7.230 [IQR 7.162–7.360] vs. normal liver median 7.105 [IQR 6.999–7.170]) (Figure 2D).

### Table 1: HB patient characteristics and CAIX expression status.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at sampling (years, age group)</th>
<th>Sex (Male/Female)</th>
<th>PRETEXT</th>
<th>Histology</th>
<th>Surgery</th>
<th>Chemo</th>
<th>CAIX (+/+/++)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB1</td>
<td>&gt;7</td>
<td>M</td>
<td>3, P</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>+</td>
</tr>
<tr>
<td>HB2</td>
<td>3-7</td>
<td>M</td>
<td>4, B</td>
<td>Fetal</td>
<td>TX</td>
<td>SIOPEL-4, sorafenib, vincristine, etoposide</td>
<td>+</td>
</tr>
<tr>
<td>HB3</td>
<td>3-7</td>
<td>F</td>
<td>3, M</td>
<td>n/a</td>
<td>TX</td>
<td>SIOPEL-4, sorafenib, vincristine, fluorouracil</td>
<td>++</td>
</tr>
<tr>
<td>HB4</td>
<td>3-7</td>
<td>M</td>
<td>3, A1</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>+</td>
</tr>
<tr>
<td>HB5</td>
<td>3-7</td>
<td>F</td>
<td>3, V, E</td>
<td>Fetal, embryonal</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>–</td>
</tr>
<tr>
<td>HB6</td>
<td>1-3</td>
<td>M</td>
<td>2, A1</td>
<td>Fetal, epithelial</td>
<td>Resection</td>
<td>SIOPEL-4</td>
<td>+</td>
</tr>
<tr>
<td>HB7</td>
<td>3-7</td>
<td>M</td>
<td>Unknown</td>
<td>Epithelial, macrotrabecular</td>
<td>TX</td>
<td>n/a</td>
<td>–</td>
</tr>
<tr>
<td>HB8</td>
<td>&gt;7</td>
<td>M</td>
<td>M</td>
<td>Fetal, well-differentiated</td>
<td>TX</td>
<td>n/a</td>
<td>+</td>
</tr>
<tr>
<td>HB9</td>
<td>&lt;1</td>
<td>F</td>
<td>3, A1</td>
<td>Fetal, epithelial</td>
<td>Resection</td>
<td>SIOPEL-4</td>
<td>–</td>
</tr>
<tr>
<td>HB10</td>
<td>&gt;7</td>
<td>F</td>
<td>4, E1, H1</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>++</td>
</tr>
<tr>
<td>HB11</td>
<td>&lt;1</td>
<td>M</td>
<td>2, A1</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>Cisplatin</td>
<td>+</td>
</tr>
<tr>
<td>HB12</td>
<td>1-3</td>
<td>M</td>
<td>2</td>
<td>Mixed epithelial/mesenchymal</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>–</td>
</tr>
<tr>
<td>HB13</td>
<td>3-7</td>
<td>F</td>
<td>4, M</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>+</td>
</tr>
<tr>
<td>HB14</td>
<td>1-3</td>
<td>M</td>
<td>4, M, V</td>
<td>Embryonal, mixed</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>++</td>
</tr>
<tr>
<td>HB15</td>
<td>3-7</td>
<td>M</td>
<td>2, H1</td>
<td>Fetal, epithelial</td>
<td>Resection</td>
<td>SIOPEL-4</td>
<td>++</td>
</tr>
<tr>
<td>HB16</td>
<td>3-7</td>
<td>F</td>
<td>2, P2</td>
<td>Embryonal</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>–</td>
</tr>
<tr>
<td>HB17</td>
<td>1-3</td>
<td>M</td>
<td>3</td>
<td>Fetal, epithelial</td>
<td>TX</td>
<td>SIOPEL-4</td>
<td>–</td>
</tr>
<tr>
<td>HB18</td>
<td>3-7</td>
<td>F</td>
<td>3, M</td>
<td>Fetal, epithelial</td>
<td>Resection</td>
<td>n/a</td>
<td>++</td>
</tr>
<tr>
<td>HB19</td>
<td>1-3</td>
<td>F</td>
<td>4</td>
<td>Fetal, epithelial, well differentiated</td>
<td>TX</td>
<td>n/a</td>
<td>+</td>
</tr>
<tr>
<td>HB20</td>
<td>1-3</td>
<td>F</td>
<td>3</td>
<td>Epithelial, embryonal and fetal</td>
<td>Resection</td>
<td>n/a</td>
<td>+</td>
</tr>
<tr>
<td>HB21</td>
<td>1-3</td>
<td>F</td>
<td>2</td>
<td>Mixed epithelial/mesenchymal, teratoid features</td>
<td>Resection</td>
<td>n/a</td>
<td>++</td>
</tr>
</tbody>
</table>

TX = liver transplantation.
++ = high CAIX expression.
+ = intermediate CAIX expression.
- = no CAIX expression.
n/a = data not available.

### 3.3 Hypoxia induces CAIX expression in cell models of HB

We used cell culture models to investigate whether low oxygen tension induces CAIX expression in HB. The immortalized human HB cell line...
HUH6 or the PDX-derived cell lines HB-295 and HB-303 were cultured in a hypoxic chamber or normoxic incubator for 48 h. All three HB cell lines demonstrated little or no baseline CAIX mRNA expression when cultured under normoxia (Figures 3A–C). CAIX mRNA expression was markedly upregulated in hypoxic cells compared to normoxic controls, with increases of 740-fold in HUH6 (Figure 3A), 165-fold in HB-295 (Figure 3B), and 6.7-fold in HB-303 cells (Figure 3C). Similarly, hypoxia induced 6- to 50-fold increases in CAIX protein levels (Figures 3D–I).

Next, we assessed the impact of 100 µM SLC-0111 on CAIX mRNA and protein expression under normoxic and hypoxic conditions. In normoxia, CAIX mRNA expression remained invariant after SLC-0111 treatment in all three cell models (Figures 3A–C). HB cells cultured under hypoxia and treated with SLC-0111 demonstrated a 40-60% reduction in CAIX mRNA expression compared to vehicle treated control cells (Figures 3A–C). Following SLC-0111 treatment, levels of CAIX protein decreased significantly in hypoxic HUH6 cells but not in HB-295 or HB-303 cells (Figures 3D–I).

3.4 SLC-0111 treatment attenuates HB cell viability in monolayer and spheroid cultures

To explore the effects of CAIX inhibition on HB cell survival in monolayer and spheroid cultures, we measured ATP concentrations, a surrogate for cell viability, following exposure of cells to increasing amounts of SLC-0111. In monolayer cultures, HUH6 cell viability decreased in a dose-dependent manner both in normoxia and hypoxia (Figure 4A). As with HUH6 cells, the impact of SLC-0111 on the viability of HB-295 monolayer cultures was more pronounced in normoxic than hypoxic conditions (Figure 4C). HB-303 had a dissimilar response to SLC-0111 than the other two models; cell viability increased with doses of 50-100 µM and with doses of 125-175 µM a modest decrease in viability was observed (Figure 4E).

The spatiotemporal distribution of oxygen in solid cancers cannot fully be mimicked in monolayer cell cultures. Instead, spheroids more closely resemble the 3-dimensional architecture of solid tumors, as oxygen levels differ for cells exposed directly to growth medium vs. those located in the inner parts of spheroids (42). To further assess the effects of SLC-0111 on HB cells, we used spheroids cultured in normoxia. SLC-0111 elicited a decrease in viability in all three HB spheroid models (Figures 4B, D, F). We also noticed spontaneous expression of CAIX in HB spheroids under normoxic conditions, whereas the cells grown in 2D showed negligible CAIX expression (Supplementary Figure 1).

3.5 HB cell motility is impaired by SLC-0111 treatment

Several studies have reported decreased cell motility after pharmacological inhibition of CAIX or silencing of the CAIX gene.
In our HB cell models, migration rates decreased significantly after 20 h treatment with 100 µM SLC-0111 compared to control cells both under normoxic and hypoxic conditions (Figures 5A–C). SLC-0111 had the most drastic effect on migration in HUH6 cells, wherein motility decreased approximately 70% in normoxia and 40% in hypoxia after 20 h of SLC-0111 treatment (Figure 5A). Hypoxia increased the migratory capacity of HB-295 cells compared to normoxic control cells, and SLC-0111 reduced motility in both normoxia and hypoxia (Figure 5B). A modest reduction in migration was observed in HB-303 cells treated with SLC-0111. In these cells the decrease was approximately 30% in normoxia and 35% in hypoxia compared to corresponding vehicle treated controls (Figure 5C).

3.6 Transcriptomic changes induced by SLC-0111 diverge in normoxic and hypoxic conditions

As noted above, SLC-0111 decreased viability and motility in HB cells even under normoxic conditions when CAIX expression was undetectable or extremely low, suggesting that the drug may have CAIX-independent effects. To explore transcriptomic changes induced by SLC-0111 treatment, we performed RNA sequencing analysis for HUH6 cells treated with 100 µM SLC-0111 for 48 h under either normoxia or hypoxia. First, we assessed global gene expression alterations triggered by hypoxia compared to baseline expression in normoxia. A total of 2876 DEGs were observed of which 2155 genes were upregulated and 721 were downregulated (Supplementary Figure 2; Supplementary Table 1). The three most upregulated protein coding genes were gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2), CAIX, and aquaporin 10 (AQP10) (Figure 6; Supplementary Table 2). Regulatory factor X6 (RFX6), acyl-CoA thioesterase 12 (ACOT12), and adrenoceptor alpha 2A (ADRA2A) were the most downregulated protein coding genes under hypoxia in comparison to normoxia (Figure 6; Supplementary Table 2).

Next, we assessed the effects of SLC-0111 on the HUH6 cell transcriptome. In normoxia, we observed 304 upregulated genes and 96 downregulated genes after SLC-0111 treatment (Supplementary Table 1). Under hypoxic conditions, SLC-0111 induced upregulation of 175 genes and downregulation of 312 genes (Supplementary Table 2).
Altogether, 76 genes were differentially expressed in both normoxic and hypoxic HUH6 cells treated with SLC-0111 (Figure 7D). Of these 76 genes, 15 genes were downregulated both in normoxia and hypoxia, 60 genes were upregulated in both conditions, and one gene was differentially regulated in hypoxia and normoxia (Figure 7A; Supplementary Table 3). Molecular functions associated with these overlapping genes included semaphorin binding, protein-arginine deaminase activity, and protease binding (Figure 7B). Metal ion related biological processes were highly overrepresented in SLC-0111 treated cells (Figure 7C). We also characterized overlaps in genes dysregulated in HB patient samples and expression alterations caused by SLC-0111 in HUH6 cells. A total of 7411 DEGs (Supplementary Table 1) were noted in HB vs NL, and 35 of these genes were also differentially expressed in HUH6 cells following SLC-0111 administration (Supplementary Table 1). SLC-0111 treatment of HUH6 cells caused upregulation...
of 20 genes that were downregulated in HB tumor tissue (Table 2), including the tumor suppressor genes MT1G, MT1X, MT2A, OTC, PCK2, PGLYRP2, SERPINC1, and NR1I3. Three genes (FOXJ1, PRRT1, and TSSK5P) were downregulated in SLC-0111 treated HUH6 cells and upregulated in HB tumor tissue (Table 2).

### 3.7 Target prediction analysis for SLC-0111

To identify other potential targets for SLC-0111, we performed in silico target prediction analysis with two online tools (SwissTargetPrediction and SUPERpred). We combined the common predicted targets from both tools (Table 3). In addition to CAIX and CAXII, SLC-0111 had high expected probability of binding CAII (Table 3). Other identified targets included histone deacetylase (HDAC) 3, thymidylate synthase (TYSY), nuclear factor NF kappa-B inhibitor kinase alpha (CHUK), mammalian target of rapamycin (mTOR), cyclin dependent kinases (CDKs) 1/2/4/5, and phosphatidylinositol 3-kinases PK3CA, PK3CB, and PK3CG (Table 3).

### 4 Discussion

Hypoxia triggers metabolic reprogramming in tumor cells, resulting in decreased intracellular pH levels (46). To counter this acidic stress, cancer cells induce the expression of CAIX (11). In various malignancies, CAIX expression associates with advanced
disease and treatment failure, underscoring its potential as a biomarker and treatment target (37–41). We found that CAIX is expressed in most HB samples and is associated with unfavorable clinical outcome. Our findings echo studies of adult liver cancer, wherein high CAIX expression has been linked to treatment resistance, recurrence, and unfavorable outcome (47, 48). Huang et al. reported a diffuse perinecrotic localization of CAIX in hepatocellular carcinoma (HCC) tissues (48). Similarly, we observed CAIX immunoreactivity in perinecrotic regions and in small clusters in the middle of viable tumor tissue in HB specimens. Cancer stem cells (CSCs) facilitating tumorigenicity and metastasis are thought to reside in specific niches within tumors, including perinecrotic regions (49). Of note, CAIX expression has been suggested to support CSC survival in PDX-models of cervical and breast cancer (50, 51).

Upregulation of CAIX expression has been observed in numerous cancer cell lines in response to hypoxia (52–56). In keeping with these studies, we found that CAIX expression was strongly upregulated at the mRNA and protein levels in HB cell models exposed to hypoxic conditions, while its baseline expression in normoxia was extremely low. Treatment with SLC-0111 abrogated hypoxia-induced CAIX mRNA expression in all three HB cell lines studied but caused a notable decrease in CAIX protein level in only one cell line. This may be explained by the fact that CAIX protein and mRNA expression were measured at the same timepoint. Owing to protein turnover rates, it may take longer to see a decrease in protein levels compared to RNA levels.

SLC-0111 is a ureido-sulfonamide inhibitor of CA that has been reported to target hypoxia-induced CAIX mRNA expression in all three HB cell lines studied but caused a notable decrease in CAIX protein level in only one cell line. This may be explained by the fact that CAIX protein and mRNA expression were measured at the same timepoint. Owing to protein turnover rates, it may take longer to see a decrease in protein levels compared to RNA levels.

SLC-0111 is a ureido-sulfonamide inhibitor of CA that has been reported to target hypoxia-induced CAIX and CAXII with a high selectivity (57–59). A multitude of novel SLC-0111 analogues have recently been developed to inhibit these cancer-associated enzymes with even better selectivity compared to the classical compound (60). Since SLC-0111 acts mechanistically as an inhibitor of CAIX enzymatic activity (61), it was surprising to observe a drastic

![FIGURE 5](image_url)
impact on CAIX mRNA levels in HB cells with low basal CAIX expression in the present study. A similar reduction in hypoxia-induced CAIX mRNA expression after SLC-0111 treatment was observed in breast cancer cells (45). Based on these findings it is possible that inhibition of CAIX activity has a negative regulatory effect on its transcription.

Tumor cell motility is a prerequisite for metastasis. Multiple studies have demonstrated an association between increased migratory or invasive capability and high CAIX expression in cancer (19, 62–65). Consistent with those reports, the motility of HB cells was reduced when CAIX function was inhibited with SLC-0111. Mechanistically, CAIX has been shown to interact with cell adhesion proteins, matrix metalloproteinases, integrins, and ion exchangers to facilitate migration and invasion (63, 66–68). Interactome studies are required to clarify which proteins are co-operating with CAIX in HB cells.

Interestingly, we noticed that SLC-0111 attenuated HB cell viability and motility when there was no observable CAIX expression, suggesting that there may be alternative targets for this drug. SLC-0111 is an efficient nanomolar inhibitor of CAIX and CAII, consistent with our target prediction analysis (57). In metastatic lung, colorectal, and breast cancer models, combination therapy with SLC-0111 and the HDAC inhibitor SAHA has demonstrated higher potency than these agents as monotherapy (70). Moreover, this multi-drug treatment associated with increased p53 and histone H4 acetylation (70). Our target prediction analyses suggested that SLC-0111 may interact with HDAC3. SLC-0111 has potential to act as an epigenetic modifier and may potentiate HDAC inhibitors partially by targeting the very same proteins. We also observed enrichment of cell cycle regulation related proteins (CDK1/2/4/5) in predicted targets of SLC-0111. This may be one of the mechanisms how SLC-0111 reduces cell viability in normoxia and should be validated in the future. Further investigations are needed to understand SLC-0111 mechanisms of action in the absence of CAIX expression in HB as well as other tumor types.

SLC-0111 treatment triggered distinct patterns of gene expression in normoxic vs. hypoxic HUH6 cells. This suggests that the mechanism of action of SLC-0111 may be environment-dependent. Notably, we found that SLC-0111 enhanced expression of eight genes (MT1G, MTIX, MT2A, OTC, PCK2, PGLYRP2, SERPINC1, and

---

FIGURE 6
Hypoxia-induced transcriptomic alterations in HUH6 cells. Heatmap of the 25 most downregulated and the 25 most upregulated differentially expressed genes in RNA sequencing analysis performed for cells grown under normoxic or hypoxic conditions sorted by logFC. The three most up- and downregulated protein coding genes are highlighted in red color.
NR1I3) under both normoxic and hypoxic conditions. Each of these genes has been shown to be epigenetically silenced or deactivated in HB or other liver malignancies, and restoring expression was associated with improved prognosis, reduced cell viability, and/or decreased metastatic capacity (71–77).

Conversely, SLC-0111 attenuated expression of FOXJ1 in HUH6 cells under normoxia and hypoxia. Overexpression of FOXJ1 has been linked with poor prognosis and increased proliferation rate in HCC (78). Based on these transcriptomic changes and earlier studies, we propose that SLC-0111 may act as an epigenetic modifier activating tumor suppressor genes and downregulating oncogenes in addition to functioning as a CAIX inhibitor. This mechanism could explain the drastic impact of SLC-0111 on HB cell viability and motility in the absence of observable CAIX expression. More investigations are needed to delineate the exact effectors.

To date, one clinical trial of SLC-0111 has been reported. In that Phase 1 study, no objective responses were observed in adults with advanced solid tumors, but 2 out of 17 heavily pre-treated patients had stable disease for up to 24 weeks (24). It must be emphasized that confirmed CAIX tissue expression was not used as an inclusion criterion for that study. There is also a Phase Ib clinical trial on the efficacy of SLC-0111 in combination with gemcitabine in CAIX-positive pancreatic cancer patients (79). These and future trials will hopefully identify patients who may benefit from SLC-0111.

**FIGURE 7**

Impact of SLC-0111 on gene expression in normoxic and hypoxic HUH6 cells. RNA sequencing analysis identified 243 upregulated and 81 downregulated genes after SLC-0111 treatment in normoxia (A). In hypoxia the corresponding numbers were 115 upregulated and 296 downregulated (A). 60 genes were upregulated and 15 downregulated both in normoxia and hypoxia (A). One gene was upregulated in normoxia but downregulated in hypoxia (A).

Enriched molecular functions in overlapping genes (B). Enriched biological processes in overlapping genes (C). Heatmap of overlapping differentially regulated genes in hypoxia and normoxia (D).
### Table 2: Overlaps in genes dysregulated in HB patient samples and expression alterations caused by SLC-0111 in HUH6 cells.

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Gene</th>
<th>Up/Downregulated (HB tissue vs. NL)</th>
<th>Up/Downregulated (SLC-0111 vs. DMSO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSG00000125730</td>
<td>C3</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000128965</td>
<td>CHAC1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000140465</td>
<td>CYP1A1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000129654</td>
<td>FOXJ1</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>ENSG00000123689</td>
<td>G0S2</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000229005</td>
<td>HNF4A-AS1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000139269</td>
<td>INHBE</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000214856</td>
<td>KRT16P1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG000001466816</td>
<td>LDHD</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000146166</td>
<td>LGSN</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000125144</td>
<td>MT1G</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000187193</td>
<td>MT1X</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000125148</td>
<td>MT2A</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000276980</td>
<td>NA</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000143257</td>
<td>NR1I3</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000036473</td>
<td>OTC</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000108889</td>
<td>PCK2</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000161031</td>
<td>PGLYRP2</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000204314</td>
<td>PRRT1</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>ENSG00000117601</td>
<td>SERPINC1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG0000008513</td>
<td>ST3GAL1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG000000108327</td>
<td>STAB1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>ENSG00000227473</td>
<td>TSSK5P</td>
<td>↑</td>
<td>↓</td>
</tr>
</tbody>
</table>

↓ = gene downregulated, ↑ = gene upregulated.

### Table 3: Predicted bioactive targets of SLC-0111.

<table>
<thead>
<tr>
<th>Uniprot ID</th>
<th>Target</th>
<th>Target Class</th>
<th>Swiss Target Prediction (probability)</th>
<th>SUPERpred (probability)</th>
</tr>
</thead>
<tbody>
<tr>
<td>O43570</td>
<td>CAXII</td>
<td>Lyase</td>
<td>0.99283030414</td>
<td>1.0</td>
</tr>
<tr>
<td>Q16790</td>
<td>CAIX</td>
<td>Lyase</td>
<td>0.99283030414</td>
<td>1.0</td>
</tr>
<tr>
<td>P09918</td>
<td>CAI</td>
<td>Lyase</td>
<td>0.99283030414</td>
<td>1.0</td>
</tr>
<tr>
<td>P00915</td>
<td>CAI</td>
<td>Lyase</td>
<td>0.0978745343258</td>
<td>0.98</td>
</tr>
<tr>
<td>P54132</td>
<td>BLM</td>
<td>Enzyme</td>
<td>0.0978745343258</td>
<td>0.98</td>
</tr>
<tr>
<td>Q00535</td>
<td>CDK5</td>
<td>Kinase</td>
<td>0.0978745343258</td>
<td>0.9</td>
</tr>
<tr>
<td>O15379</td>
<td>HDAC3</td>
<td>Eraser</td>
<td>0.0978745343258</td>
<td>0.89</td>
</tr>
<tr>
<td>P17948</td>
<td>VGFR1</td>
<td>Kinase</td>
<td>0.0978745343258</td>
<td>0.87</td>
</tr>
<tr>
<td>P10721</td>
<td>KIT</td>
<td>Kinase</td>
<td>0.0978745343258</td>
<td>0.85</td>
</tr>
<tr>
<td>P24864</td>
<td>CCNE1</td>
<td>Kinase</td>
<td>0.0978745343258</td>
<td>0.83</td>
</tr>
<tr>
<td>P04818</td>
<td>TYSY</td>
<td>Transferase</td>
<td>0.0978745343258</td>
<td>0.83</td>
</tr>
<tr>
<td>P36888</td>
<td>FLT3</td>
<td>Kinase</td>
<td>0.0978745343258</td>
<td>0.726</td>
</tr>
</tbody>
</table>

(Continued)
We suggest that the role of SLC-0111 as a potential epigenetic regulator of tumor suppressor genes should be considered when planning future clinical trials. Pediatric clinical trials are needed to confirm the safety of SLC-0111 in this population.

One limitation of our study is that the impact of SLC-0111 on HB was not examined \textit{in vivo}. Another shortcoming is that several of the \textit{in vitro} experiments were conducted in monolayer cultures which do not fully recapitulate oxygen gradients in tumor tissue.

\begin{table}
\centering
\begin{tabular}{llllll}
\hline
Uniprot ID & Target & Target Class & Swiss Target Prediction (probability) & SUPERpred (probability) \\
\hline
P24941 & CDK2 & Kinase & 0.097874343258 & 0.72 \\
P08235 & MCR & Nuclear receptor & 0.097874343258 & 0.72 \\
P06493 & CDK1 & Other cytosolic protein & 0.097874343258 & 0.7 \\
P23219 & PGH1 & Oxidoreductase & 0.097874343258 & 0.67 \\
P04629 & NTRK1 & Kinase & 0.097874343258 & 0.67 \\
P42345 & MTOR & Kinase & 0.097874343258 & 0.67 \\
P42338 & PKSCB & Enzyme & 0.097874343258 & 0.64 \\
P48736 & PK3CG & Enzyme & 0.097874343258 & 0.62 \\
O15111 & CHUC & Kinase & 0.097874343258 & 0.62 \\
O00444 & PLK4 & Kinase & 0.097874343258 & 0.61 \\
P53667 & LIMK1 & Kinase & 0.097874343258 & 0.6 \\
P11802 & CDK4 & Kinase & 0.097874343258 & 0.6 \\
P42336 & PK3CA & Enzyme & 0.097874343258 & 0.6 \\
P40763 & STAT3 & Transcription factor & 0.097874343258 & 0.58 \\
P45984 & MK09 & Kinase & 0.097874343258 & 0.57 \\
Q9HAZ1 & CLK4 & Kinase & 0.097874343258 & 0.54 \\
P49759 & CLK1 & Kinase & 0.097874343258 & 0.51 \\
P35218 & CAHSA & Lyase & 0.097874343258 & 0.5 \\
\hline
\end{tabular}
\caption{Continued}
\end{table}

\begin{figure}
\centering
\includegraphics[width=0.8\textwidth]{fig8.png}
\caption{Schematic illustration of the findings.}
\end{figure}
The key findings of this study are summarized in Figure 8. All in all, CAIX is expressed in the majority of HBs and may have potential as a prognostic marker. In HB cell culture models, hypoxia induces CAIX expression, and the CAIX inhibitor SLC-0111 reduces HB cell survival and motility. Our results also suggest that SLC-0111 may have CAIX-independent effects. We speculate that SLC-0111 administration may restore expression of tumor suppressor genes in HB via epigenetic mechanisms.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/ . GSE185937.

Ethics statement

The studies involving human participants were reviewed and approved by Helsinki University Hospital institutional ethics committee. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

KE, MP, SP, and MH: conceptualization and research design. KE, MP, EL, RN, TS, JL, DW, SP and MH: acquisition, analysis, or interpretation of data. SC: establishing and providing PDX cell models. MP: Preparing the final Figures. KE: writing the first draft. KE, MP, EL, RN, TS, JL, SC, DW, SP, and MH: reviewing and editing. KE, MP, EL, RN, TS, JL, SC, DW, SP, and MH: final approval of the manuscript version to be published. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by Doctoral Program in Clinical Research at University of Helsinki Funds, Finska Läkaresällskapet, Helsinki University Central Hospital Research Grants, Päivikki and Sakari Sohlberg Foundation, and Sigrid Juselius Foundation and Lasten Syöpäsäätiö Väre (Väre Foundation).

Acknowledgments

We thank Professor Silvia Pastorekova for providing the M75 antibody, Docent Ras Trokovic and MSc Joonas Sokka for helping us with the XVivo incubation system, and Dr. Antti Hänninen for assisting with the Opera Phenix High Content Screening System. Institute for Molecular Medicine Finland FIMM Technology Centre Genotyping lab and (University of Helsinki) is thanked for the cell line authentication.

Conflict of interest

Author Stefano Cairo has formerly been employed by the company XenTech and is currently employed by the company Champions Oncology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1118268/full#supplementary-material

References


Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment.


